The 100,000 TB deaths yearly in Indonesia is a rounded estimate from sources like USAID (93,000 in 2018) and WHO. Recent 2023 data shows a TB death rate of 44 per 100,000, equating to about 122,115 deaths with Indonesia’s population of 277.5 million. Variations arise due to reporting differences and disruptions like COVID-19. For the M72/AS01E vaccine trials, data comes from WHO, Wellcome, and the New England Journal of Medicine, noting 54% efficacy in Phase 2b trials. Concerns about safety and consent are noted, but trials follow WHO ethical guidelines. Check WHO’s Global Tuberculosis Report and USAID’s Indonesia TB Roadmap for details.
Indonesia is part of global Phase 3 trials for the M72/AS01E TB vaccine, funded by the Bill & Melinda Gates Foundation. The trials, involving 20,000 participants across seven countries, aim to combat TB, a major health issue in Indonesia with 100,000 deaths yearly. The Health Ministry and local universities oversee the process, following WHO ethical guidelines with informed consent. While concerns about safety and exploitation exist, no evidence of misconduct was found. The trials could save millions of lives, but some question if resources should focus on existing treatments. Public distrust remains a challenge.